Introduction
Accurate staging of cancer is critical to predict overall prognosis as well as to decide on the most appropriate treatment(s), and to evaluate the tumour's response to those treatments. The role of lymph node metastasis has been well-demonstrated in the systemic dissemination of cancer, and therefore the lymph node status is of vital importance in the staging process [1; 2] . Current lymph node staging procedures are based on structural abnormalities (such as size and shape) and pathological examination of biopsies, guided or not by imaging-based detection of the sentinel lymph node(s) (SLNs). The SLN concept describes the preferential lymphatic metastasis of a primary tumour to one or more regional lymph nodes. Identification of the SLNs in current clinical practice is performed using dyes for direct intra-operative visualization and radiolabelled lymphotropic colloids coupled with nuclear imaging. When injected near the primary tumour, the imaging agent is taken up by the adjacent lymphatic and transported to the SLNs. In Australia for instance, the clinical lymphotropic radiotracer is 99m
Tc-antimony trisulfide [3] . For cancers where the lymphatic network is well mapped, such as breast cancer, biopsy-based assessment of SLN status is commonly used to minimize the burden of lymphadenectomy side-effects and associated morbidity. The relevance and utility of the SLN concept in other solid tumours such as gastrointestinal cancer has been more controversial with continued debate regarding its role, if any, in staging and treatment algorithms [4; 5] . The latter, however, is more the consequence of challenges associated with precise lymphatic mapping for such cancers rather than pathophysiological considerations. In the context of many deeply-situated cancers, current lymphoscintigraphy procedures are severely limited by the inherent low spatial resolution of nuclear imaging as well as by the "shine through effect" associated with the close proximity of SLNs to the primary tumour [6] .
There is therefore a critical need to develop novel combinations of lymphotropic contrast agents and related imaging modalities [7] . Fostered by recent advances in nanotechnology, nanoparticle contrast agents are being actively developed and are now entering the clinical arena [8; 9] . In the context of lymphatic mapping, a range of novel nanoparticle contrast agents compatible with imaging modalities routinely used in the clinical practice have been developed, including iron oxide nanocrystals for magnetic resonance imaging [10] , high atomic number nanoparticles (e.g.
gold, bismuth, iodine) for CT imaging [11] , nanobubbles and nanoemulsions for ultrasound imaging [12; 13] , plasmonic nanoparticles for photoaccoustic imaging [14] , and quantum dots for fluorescence-based imaging [15] .
Although the behaviour of nanoparticle contrast agents within the lymphatics is directly correlated to their size and, to a lesser extent, their non-specific affinity for lymphatic tissues, the structure-activity relationship remains unclear. A general rule is that small molecules, such as those based on blue dyes, diffuse rapidly through the lymphatics and reach the SLNs within minutes. On the other hand, larger lymphotropic agents such as antimony-based radiocolloids are retained longer in the SLNs, which minimizes the risk of erroneous diagnosis but their slow diffusion rate often precludes intraoperative mapping of the SLNs. In an attempt to solve this dilemma, small lymphotropic agents designed to bind to macrophages and therefore to be retained in the lymph nodes are being developed. The most advanced of these next generation lymphotropic agents, Lymphoseek, is a 99m
Tc labelled dextran-mannose conjugate designed to have increased retention in the SLNs [16; 17] . Two Phase 3 multi-centre clinical trials have been completed and the U.S. Food and Drug Administration (FDA) has recently accepted a New Drug Application for this radiopharmaceutical. Although such agents are typically associated with faster clearance from the injection site when compared to relatively large colloid-based agents, which could aid in reducing the "shine-through effect", they remain intrinsically limited by the poor spatial resolution of nuclear imaging. In addition, the very rapid transport of such agents to the SLNs makes it challenging to accurately image lymphatic drainage.
Based on the previous findings, we hypothesize here that nanoparticle contrast agents in the 10- 18]. A recent study illustrated the potential of such agents using mannose-conjugated gold nanoparticles, which were found to accumulate in the popliteal lymph nodes after injection in rat's footpads [19] .
The aim of this work was to investigate the lymphatic transport of small solid nanoparticles with high affinity for CD45 expressing cells. CD45 is a transmembrane glycoprotein of the leukocytespecific receptor-like protein tyrosine phosphatase expressed at high density on nucleated haematopoietic cells. It is therefore a good molecular target candidate for delivery to lymphoid cells. 18 nm gold nanoparticles used here as a model for solid nanoparticle lymphotropic agents were conjugated with an anti-CD45 antibody, and their properties were characterized in vitro and in vivo. A critical requirement in the experimental design was avoiding aggregation during the bioconjugation procedure. This was achieved using a polymeric coating based on polyethylene glycol molecules (PEG) with different molecular weights designed to maximized bioconjugation yield while maintaining the colloidal stability of the nanoparticles. As a result of the high binding affinity to CD45+ lymphoid cells, immunotargeted nanoparticles were retained in the popliteal and axillary lymph nodes after interstitial injection in mouse fore/hind paw while their nonconjugated counterparts were cleared from the lymphatics rapidly.
Materials and Methods

Materials
Chloroauric acid (HAuCl 4 ·3H 2 O), sodium citrate, N-hydroxysuccinimide (NHS), N-(3-
, and a silver enhancer kit were obtained from Sigma-Aldrich and used as received from the manufacturer without further purification. Water used in the experiments was purified with a Millipore water treatment system (organic content less than 5 ppb). Polyethylene glycol thiol (HS-PEG-COOH) with an average molecular weight of 5000 g/mol was purchased from Rapp polymer Gmbh. Short chain length PEG thiol acid (molecular weight 458.6) were purchased from Polypure. Mouse CD 45 (Ptprc monoclonal antibody) was purchased from Abnova.
Synthesis and Biofunctionalization of the Lymphotropic Agents
Gold nanoparticle synthesis and surface modification with PEG have been carried with minor modification from our previous study [20] . Briefly, citrate coated gold nanoparticles were prepared using the standard citrate method. Mixed thiolated PEG molecules comprising carboxylic functionalized short chain length PEG molecules (Fw 458.6) and PEG with longer chain length (Fw 5000) were used to stabilize the gold nanoparticles and enable optimal bioconjugation of monoclonal antibodies to the nanoparticles. The mixture of PEGs were prepared at a concentration of 1 mg/mL and mixed with a ratio of 4:1 (Fw 5000: Fw 458.6). The mixed PEG solution was added to the gold nanoparticle solution under vortex and left to react for at least 6 hours at room temperature. After purification by centrifugation, the carboxyl groups on the PEGylated gold nanoparticles (1.0 mM, 1 mL) were activated using NHS (20 mg/mL) and EDC (15 mg/mL) for 5 min. The nanoparticle suspensions were then quickly centrifuged and resuspended into PBS (900 µL). Mouse anti-CD 45 antibody (0.5 mg/mL, 0.1 mL) was added rapidly to the activated gold nanoparticles and left to react at room temperature and stored at The physicochemical properties of the nanoparticles before and after the bioconjugation were determined using UV-Vis absorption and dynamic light scattering. UV-Vis spectra were determined using a Varian Cary 5 UV-Vis-NIR spectrophotometer at room temperature. The hydrodynamic diameter of gold nanoparticles was measured via dynamic light scattering using a
Zetasizer Nano ZS equipped with a 633nm He-Ne laser (Malvern Instruments). The morphology and size distribution of gold nanoparticles prepared on a copper grid were analysed using a Philips CM100 transmission electron microscope (TEM).
Binding Affinity of the Anti-CD45 Bioconjugated Nanoparticles to Macrophages
To determine the active targeting effect of the immuno-functionalized gold nanoparticles, an in vitro assay was designed using RAW 264.7 macrophages used here as a model for lymphatic was determined by manual cell counting. The bright field microscopy study was complemented with reflectance confocal microscopy (LSM510) which provided higher imaging quality and increased sensitivity to the presence of the gold nanoparticles. In reflectance confocal microscopy, the high light scattering associated with plasmonic nanoparticles enable observations at the single nanoparticles level [21; 22] . To determine the three dimensional intracellular locations of the total NPs, vertical spatial images of nanoparticles within the RAW cells were generated by z-scans in 0.25 μm steps. The z-stack images were overlaid for each sample to confirm the targeting ability of different functionalized gold nanoparticles to cells. 
Lymphatic Transport and Retention of the anti-CD45 Nanoparticles
Results and discussion
Design of the Bioconjugated Contrast Agents
Gold nanoparticles were chosen here as a model nanoparticle contrast agent owing to the existence of well-established synthesis routes with excellent control of the particle size as well as their unique optical properties [23] . Nanoparticles with an average diameter of 18 nm were synthesized and the size was confirmed by TEM measurement (Figure 2 
In vitro Binding Affinity of the anti-CD45 Nanoparticles to Lymphatic Cells
To compare the in vitro cellular binding of the nanoparticles targeted or not to CD45+ cells, these two groups of nanoparticles were incubated with macrophages for 2 h at a relatively low concentration of gold nanoparticles (0.01 mM and 0.04 mM) chossen to avoid binding-saturation. images could be associated with endocytotic internalization of the nanoparticles after binding to the macrophages [30] . These in vitro studies confirmed that the PEG coating drastically inhibited non-specific binding to macrophages while enabling efficient bioconjugation with biological ligands. The protective effect against phagocytosis of PEG-based nanoparticles coating originates in reduction of protein fouling and is strongly dependant on the properties of the polymeric adlayers [31] .
Lymphatic Drainage and Retention in Mice
To investigate the lymphatic drainage of the nanoparticles conjugated or not with the anti-CD45
antibodies, BALB/cByJNarl mice were injected subcutaneously in the dorsal toe of the fore/hind paw (1 mg Au / kg body weight). At various time points, the animals were sacrificed and the axillary and popliteal lymph nodes were collected and analysed using ICP-MS to determine the gold concentration. Although the drainage distribution varies between individual mice, the injection through the hind pad typically drains to the popliteal (then on to iliac) [32] . The axillary lymph node serves as the first lymph node to receive the drainage from the fore pad. agents. In a recent clinical study, the mean sentinel lymph node retention for Lymphoseek was 1.5±1.7% [33] . Similarly, 1.32 % of gold nanoparticles conjugated with mannose were retained in the popliteal nodes after injection in Wistar rats [19] . Although further studies are required, these data suggest that lymphotropic nanoparticulate contrast agents designed to bind with high affinity to lymphoid cells which intrinsically overexpress the CD45 antigen is a promising alternative to mannose-based targeting approaches. The high node retention observed in this study with anti-CD45 targeted nanoparticles was consistent to that obtained using anti-CD4 conjugated nanoparticles [28] . However, large aggregates (up to 500 nm) were found after the antibody conjugation in these studies and the size variation upon bioconjugation make it difficult to draw conclusions on transport via the lymphatic drainage [27; 28] . To unravel the complex lymphatic behaviour of exogenous contrast agents, it is critical to fully characterize their physicochemical properties and control their interactions with biological components. The latter was achieved here by using mixed PEG coatings which enabled efficient bioconjugation with monoclonal antibodies while providing excellent colloidal stability during the conjugation process and in biological environments. In addition to their protective effect against nanoparticle aggregation, PEG-based nanoparticle coatings were found to drastically increase the lymphatic drainage of phospholipid liposomes [34] . The specific effect of the PEG coating could not be tested here, since nanoparticles without PEG coating rapidly aggregated during the conjugation as well as in biological environments, which precluded meaningful investigation of the chemistry versus size effects on nanoparticle lymphatic transport.
Conclusions
The metastatic status of regional lymph nodes is the most significant prognostic factor in breast cancer, melanoma and other solid tumors with lymphatic spread. Clinical application of the Sentinel Lymph Node concept remains limited in a number of diseases due to the limitations of the current lymphotropic tracers used to identify lymphatic drainage from the primary tumor.
This study aimed to demonstrate the potential of lymphotropic nanoparticle contrast agents designed to bind with high affinity to lymphoid cells overexpressing the CD45 antigen. To this end, gold nanoparticles with a 18 nm diameter were prepared and bioconjugated with anti-CD45
antibodies through an optimized polyethylene glycol (PEG) coating designed to protect the nanoparticles from aggregation. Using a murine macrophage cell line as a model, the high binding affinity for lymphoid cells of the anti-CD45 nanoparticles was demonstrated in vitro. In contrast, unconjugated nanoparticles showed minimal non-specific binding to the macrophage thanks to the dense PEG coating. Chemical analysis of the popliteal and axillary lymph nodes of mice was conducted at different time points after subcutaneous injection of the nanoparticles in the dorsal toe of the fore/hind paw. This study confirmed the rapid lymphatic uptake and transport of the small nanoparticles. At 6 and 24 hours, the anti-CD45 targeted nanoparticles were significantly retained in the nodes and compared favourably with lymphatic tracers targeting mannose receptors. The combination of small hydrodynamic size, optimal PEG coating and high binding affinity to CD45 positive lymphoid cells appears to be suitable for the development of advanced detection agents for the SLNs. Building on this study and the availability of advanced nanoparticulates contrast agents compatible with state-of-the-art imaging modalities such as magnetic resonance imaging, we expect that improved imaging procedures for pre-and intra-operative detection of the SLNs can be developed.
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